Ditchcarbon
  • Customers
  1. Organizations
  2. Sumitomo Pharma
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated 9 days ago

Sumitomo Pharma

Company website

Sumitomo Pharma Co., Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1897, the company has a rich history marked by significant milestones, including advancements in research and development that have positioned it as a leader in innovative healthcare solutions. Specialising in prescription pharmaceuticals, Sumitomo Pharma focuses on areas such as central nervous system disorders, oncology, and regenerative medicine. Its unique approach to drug development, emphasising both quality and efficacy, has led to the creation of several groundbreaking therapies. With a strong market presence and a commitment to improving patient outcomes, Sumitomo Pharma continues to achieve notable recognition within the industry, solidifying its reputation as a trusted name in healthcare.

DitchCarbon Score

How does Sumitomo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

38

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Sumitomo Pharma's score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Sumitomo Pharma's reported carbon emissions

In 2023, Sumitomo Pharma reported significant carbon emissions, with Scope 2 emissions amounting to approximately 26,827,000 kg CO2e and Scope 3 emissions reaching about 356,214,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2020 as the baseline. Additionally, Sumitomo Pharma is targeting a 25% reduction in absolute Scope 3 emissions from purchased goods and services within the same timeframe. Over the past few years, the company has shown a trend in its emissions data. For instance, in 2022, Scope 2 emissions were about 26,518,000 kg CO2e, while Scope 3 emissions were approximately 364,869,000 kg CO2e. This indicates a slight decrease in Scope 2 emissions from 2022 to 2023, although Scope 3 emissions have remained relatively stable. Sumitomo Pharma's commitments align with the Science Based Targets initiative (SBTi), which underscores their dedication to climate action. The company is classified under the Pharmaceuticals, Biotechnology, and Life Sciences sector and operates from its headquarters in Japan. As a current subsidiary of Sumitomo Pharma Co., Ltd., these emissions data and targets are cascaded from the parent organization, ensuring a unified approach to sustainability across its operations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2017201820192020202120222023
Scope 1
41,805,000
00,000,000
00,000,000
00,000,000
-
-
-
Scope 2
38,906,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
35,270,000
00,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sumitomo Pharma's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sumitomo Pharma is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Sumitomo Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Intra-Cellular Therapies, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Lundbeck

DK
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Otsuka America Pharmaceutical, Inc

US
•
Research and development services (73)
Updated 14 days ago

Forest Laboratories, LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Indivior

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Chiesi Ltd.

GB
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.10
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy